London, UK 4/15/15—LGC, a life science–measurement and –testing company, has agreed to acquire Biosearch Technologies, a designer, developer and manufacturer of custom oligonucleotides and associated reagents for medical diagnostic, research and applied markets. The financial amount was not disclosed. Biosearch has 170 employees in the US and Europe. “Both LGC and Biosearch have a complementary range of products, thus allowing us to provide customers with a one-stop shop for a wide range of genomics applications,” commented LGC CEO Tim Robinson. “With this acquisition, we are strengthening our position within the applied-genomics market, especially the agricultural biotechnology sector, and broadening our offering to the molecular diagnostic market.” LGC will make Biosearch the US headquarters for its Genomics division. LGC stated that the combined portfolio includes DNA synthesis reagents, predesigned assays for genotyping and pathogen detection, custom probes for qPCR, DNA polymerases and KASP master mixes for PCR, and instrumentation for high-throughput DNA extraction and PCR. Laboratory services include DNA synthesis of primers and probes incorporating proprietary fluorophores and quenchers, DNA extraction, sequencing, genotyping and gene synthesis.